F Farace

686 total citations
7 papers, 563 citations indexed

About

F Farace is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, F Farace has authored 7 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Immunology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in F Farace's work include Cancer Immunotherapy and Biomarkers (3 papers), Immune Cell Function and Interaction (3 papers) and Fungal Infections and Studies (2 papers). F Farace is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Immune Cell Function and Interaction (3 papers) and Fungal Infections and Studies (2 papers). F Farace collaborates with scholars based in France. F Farace's co-authors include Philippe Vielh, Jean‐Charles Soria, David Planchard, Karim Fizazi, Nadège Vimond, Fanny Billiot, Nathalie Jacques, Françoise Drusch, Christophe Massard and Ludovic Lacroix and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and European Journal of Cancer.

In The Last Decade

F Farace

7 papers receiving 554 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F Farace France 7 437 257 156 124 112 7 563
Gayatri Premasekharan United States 10 306 0.7× 212 0.8× 151 1.0× 64 0.5× 57 0.5× 14 489
Jake Lichterman United States 7 287 0.7× 377 1.5× 142 0.9× 119 1.0× 100 0.9× 10 739
Daisy Dandan Wang United States 12 407 0.9× 298 1.2× 111 0.7× 43 0.3× 52 0.5× 17 515
Martha Zavridou Greece 12 282 0.6× 430 1.7× 127 0.8× 70 0.6× 52 0.5× 18 659
Bianca Behrens Germany 12 407 0.9× 325 1.3× 84 0.5× 116 0.9× 66 0.6× 21 598
Anne Renolen Norway 9 385 0.9× 252 1.0× 98 0.6× 49 0.4× 18 0.2× 13 468
José L. García-Puche Spain 11 258 0.6× 313 1.2× 110 0.7× 61 0.5× 28 0.3× 21 551
Dorota Kwapisz Poland 6 346 0.8× 256 1.0× 302 1.9× 45 0.4× 57 0.5× 9 608
Meleah Cameron United States 3 244 0.6× 130 0.5× 64 0.4× 52 0.4× 38 0.3× 6 386
María Jesús García-Granda Spain 5 367 0.8× 60 0.2× 94 0.6× 85 0.7× 301 2.7× 5 575

Countries citing papers authored by F Farace

Since Specialization
Citations

This map shows the geographic impact of F Farace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Farace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Farace more than expected).

Fields of papers citing papers by F Farace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Farace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Farace. The network helps show where F Farace may publish in the future.

Co-authorship network of co-authors of F Farace

This figure shows the co-authorship network connecting the top 25 collaborators of F Farace. A scholar is included among the top collaborators of F Farace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Farace. F Farace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Pailler, Emma, Nathalie Auger, Colin R. Lindsay, et al.. (2015). High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Annals of Oncology. 26(7). 1408–1415. 96 indexed citations
2.
Farace, F, Christophe Massard, Nadège Vimond, et al.. (2011). A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer. 105(6). 847–853. 325 indexed citations
3.
Cesne, Axel Le, Gilles Vassal, F Farace, et al.. (1999). Combination Interleukin-2 and Doxorubicin in Advanced Adult Solid Tumors: Circumvention of Doxorubicin Resistance in Soft-Tissue Sarcoma?. Journal of Immunotherapy. 22(3). 268–277. 15 indexed citations
4.
Escudier, Bernard, F Farace, Eric Angevin, et al.. (1994). Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. European Journal of Cancer. 30(8). 1078–1083. 44 indexed citations
5.
Escudier, Bernard, S. Antoun, B. Leclercq, et al.. (1993). Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. European Journal of Cancer. 29(5). 724–728. 21 indexed citations
6.
Farace, F, Claire Mathiot, M. Brandely, et al.. (1990). Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. Clinical & Experimental Immunology. 82(2). 194–199. 16 indexed citations
7.
Hercend, Thierry, et al.. (1990). Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.. PubMed. 9(6). 546–55. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026